A jury in Louisiana has awarded more than $9 billion in the first federal bellwether trial over claims that taking Actos increases the risk of getting bladder cancer.
The jury’s verdict, the first of nearly 3,000 lawsuits coordinated for pretrial purposes before U.S. District Judge Rebecca Doherty in Lafayette, La., emerged late Monday after nearly two months of trial.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
